THOUSAND OAKS, Calif., Oct. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that Repatha® (evolocumab) significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke. The landmark Phase 3 VESALIUS-CV trial enrolled over 12,000 high-risk patients,... Read More

Voluntary agreement meets the President’s four requests while also protecting the U.S. ecosystem responsible for America’s leadership in delivering medical breakthroughs.

PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one late breaking clinical trials oral presentation, one oral presentation, and three poster sessions will be shared at the Heart Failure Society of America (HFSA) Annual Scientific... Read More

The ABC Third Annual Policy Pulse Summit will bring together leaders across healthcare, government, industry, advocacy, and community coalitions to advance policy-driven solutions that close gaps in cardiovascular access, treatment, and prevention. This year's agenda will explore challenges such as cardiology deserts, access to evidence-based therapies, and the role of technology and trusted messengers in improving early detection... Read More